Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023402 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TSHRSMN1; SMN2SRD5A2HPGD | |
| SCHEMBL5023406 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TSHRSMN1; SMN2SRD5A2HPGD | |
| SCHEMBL13883210 | 0.90 | MCL1 (0.41) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL8098672 | 0.84 | SMN1; SMN2 (0.48) | ALDH1A1TSHRSMN1; SMN2HPGDMAPT | |
| SCHEMBL14390483 | 0.84 | SMN1; SMN2 (0.48) | ALDH1A1TSHRSMN1; SMN2HPGDMAPT | |
| SCHEMBL8097035 | 0.84 | TSHR (0.49) | TSHRSMN1; SMN2SRD5A2HPGDMAPT | |
| SCHEMBL727067 | 0.84 | TSHR (0.49) | TSHRSMN1; SMN2SRD5A2HPGDMAPT | |
| SCHEMBL4818650 | 0.82 | SMN1; SMN2 (0.47) | ALDH1A1TSHRSMN1; SMN2HPGDMAPT | |
| SCHEMBL4818645 | 0.82 | SMN1; SMN2 (0.47) | ALDH1A1TSHRSMN1; SMN2HPGDMAPT | |
| SCHEMBL934154 | 0.82 | MAPT (0.48) | ALDH1A1SMN1; SMN2HPGDMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725546-B1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-7265149-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1725546-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085235-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| US-20050203160-A1 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | disclosed |
| US-6048896-A | FOR TREATMENT OF BRAIN OR NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-04-11 | — | — | US | disclosed |
| EP-0858442-A1 | 4-PHENYL-4-OXO-2-BUTENOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997017316-A1 | 4-PHENYL-4-OXO-2-BUTENOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203160-A1 | Indolyl derivatives | PPARD, PPARA, PPARG | ALDH1A1 799/4885TSHR 145/4885SMN1; SMN2 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.